The FDA is to investigate a possible association between anti-TNF therapies and childhood cancer.
TNF blockers have become the latest drug class to undergo a detailed FDA safety review, with the potential link between these agents and cancer, particularly in children and young adults, to be assessed. Although the review could increase prescribing caution of anti-TNF therapies for children in some physicians, ultimately it will not affect the use or sales of these agents in the near-term.
The FDA, which has become increasingly safety conscious in recent years, has announced that it will investigate the possible risk of cancer in children and young adults who are receiving treatment with anti-TNF therapies.
There are currently four TNF therapies available in the US: Wyeth's and Amgen's Enbrel (etanercept), Centocor's Remicade (infliximab), Abbott's Humira (adalimumab) and UCB's Cimzia (certolizumab pegol), the last of which was recently approved in April 2008.
More
No comments:
Post a Comment